CNBC's Jim Cramer reports on the latest news regarding Moderna.

Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...

Leerink Partners analyst Mani Foroohar has reiterated their bearish stance on MRNA stock, giving a Sell rating on November 14.Don't Miss our ...

Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

Drug manufacturers saw their stock prices fall on Friday after vaccine skeptic Robert F. Kennedy Jr. was announced as Trump's ...

Piper Sandler lowered the firm’s price target on Moderna (MRNA) to $69 from $115 and keeps an Overweight rating on the shares. The firm notes ...

Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Big pharma stocks needed a shot in the arm after Donald Trump chose vaccine skeptic Robert F. Kennedy Jr. as health secretary ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

Shares of Moderna Inc. (NASDAQ: MRNA) are trading lower after President-elect Donald Trump nominated Robert F. Kennedy Jr. to ...

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against other high growth large cap stocks. BlackRock highlighted that its portfolio managers are broadly ...